All In MedTech

Device Trial Radar · NCT05534022

Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression.

Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression - Open Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Sep 26, 2022

Primary completion

Feb 27, 2025

Study completion Feb 27, 2025

Sponsor

Lead sponsor
Essilor InternationalNot on our public-company list
Sponsor type
Industry
First posted
Sep 9, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 8 years, up to 13 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a mono-centre, prospective, one-arm, unmask clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation compared to a single vision spectacle lens from the historical control group of another clinical trial NCT05331378. A total of 40 children will be recruited.

Conditions

  • Myopia

Interventions

  • Test myopia control lenses (BSL)Device

    Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Axial LengthTime frame: 12 months and 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Essilor R&D Centre Singapore

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.